Merseyside based company, Evgen, is developing Sulforadex®, a patented pharmaceutical composition with enormous potential in the prevention and treatment of prostate cancer and other cancers.

By using a portfolio of patented technologies, Evgen has uniquely positioned itself to take leadership in the clinical development of sulforaphane for the prevention and treatment of a number of human diseases.